Replies to post #40308 on OncoSec Medical Inc (ONCSQ)

[lasers]

BRIEF-Oncosec presents positive Phase 2 data for immunopulse® IL-12 in combination with Pembrolizumab
REUTERS 6:15 AM ET 10/19/2017
Symbol Last Price Change
ONCS 1.28up 0 (0%)
QUOTES AS OF 03:59:59 PM ET 10/18/2017
Oct 19 (Reuters) - Oncosec Medical Inc(ONCS)

* Oncosec presents positive Phase 2 data for Immunopulse® IL-12 in combination with Pembrolizumab demonstrating a best overall response rate (BORR) of 50 pct in predicted anti-PD-1 non-responder melanoma patients

* Oncosec - anticipate reporting initial data from PISCES/KEYNOTE-695 in mid-2018? Source text for Eikon: Further company coverage: